Results 51 to 60 of about 9,108 (216)

Ustekinumab for the treatment of psoriatic arthritis: an update. [PDF]

, 2014
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic ...
Davari, Parastoo, Fazel, Nasim, Kamangar, Faranak, Leo, Michael S   +3 more
core   +1 more source

Comparison of Ankylosing Spondylitis Disease Activity Score and Bath Ankylosing Spondylitis Disease Activity Index tools in assessment of axial spondyloarthritis activity

Rheumatology
Axial spondyloarthritis (axSpA) is an inflammatory joint disease, in which the dominant symptom is inflammatory back pain. It affects approximately 1% of the population, with a higher incidence in males.
Katarzyna Małgorzata Wiąk-Walerowicz, Ewa Wielosz   +1 more
doaj   +1 more source

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study

Rheumatology and Therapy, 2023
Introduction We studied the effect of intravenous (IV)-golimumab on fatigue and the association of fatigue improvement with clinical response post hoc in adults with active ankylosing spondylitis (AS) in the GO-ALIVE trial.
Atul Deodhar, Natalie J. Shiff, Cinty Gong, Eric K. H. Chan, Elizabeth C. Hsia, Kim Hung Lo, Alianu Akawung, Lilianne Kim, Stephen Xu, John D. Reveille   +9 more
doaj   +1 more source

Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis [PDF]

, 2011
Background We evaluated the psychometric characteristics of the Short Form 36 (SF-36) Health Survey and the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale in patients with ankylosing spondylitis (AS).
Dennis A Revicki, Anne M Rentz, Michelle P Luo, Robert L Wong   +3 more
core   +2 more sources

Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative [PDF]

Annals of the Rheumatic Diseases, 2016
Flares may be used as outcomes in axial spondyloarthritis (axSpA) trials or observational studies. The objective was to develop a definition for 'flare' (or worsening) in axSpA, based on validated composite indices, to be used in the context of clinical trial design.(1) Systematic literature review of definitions of 'flare' in published randomised ...
Gossec, Laure, Portier, Agnès, Landewé, Robert, Etcheto, Adrien, Navarro-Compán, Victoria, Kroon, Féline, van Der Heijde, Désirée, Dougados, Maxime   +7 more
openaire   +3 more sources

Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors [PDF]

, 2017
The term spondyloarthritis (SpA) is used to describe a group of multifactorial chronic inflammatory diseases characterized by a predisposing genetic background and clinical manifestations typically involving the sacroiliac joint.
Ada Aita, Breban, Daniela Basso, Giovannini, Leonardo Punzi, Maksymowych, Mario Plebani, Massova, Parma, Roberta Ramonda, Stefania Moz, Woo   +11 more
core   +1 more source

Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis

RMD Open, 2020
Objectives In axial spondyloarthritis (axSpA), higher body mass index (BMI) is associated with worse outcomes including response to biologics. Further clarity is needed on whether BMI is associated with disease activity overall, independent of treatment ...
Lianne S Gensler, Namrata Singh, Jean W Liew, Irvin J Huang, Diana N Louden   +4 more
doaj   +1 more source

Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year [PDF]

Терапевтический архив, 2017
Aim. To assess changes in the concentration of interleukin-17A (IL-17A) in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor-α (TNFα) inhibitors during a year. Subjects and methods. Examinations were made in 30 patients (22 (73.
I Z Gaydukova, A P Rebrov, A V Aparkina, E V Khondkaryan   +3 more
doaj   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail, Lynn Warner, Stacey T. Gray, Claire Hopkins, Peter H. Hwang, Sarah K. Wise, Katie M. Phillips, Ahmad R. Sedaghat   +7 more
wiley   +1 more source

Metaanálisis sobre la efectividad de la realización de ejercicio físico en pacientes con Espondilitis Anquilosante

Archives of Nursing Research, 2019
La Espondilitis Anquilosante es una patología inflamatoria, crónica y degenerativa de lasarticulaciones. Afecta mayormente a la columna vertebral y a la articulación sacroilíaca.
Alba Torres Pérez
doaj   +7 more sources